Elicio Therapeutics Phase 2 Data Misses Key Endpoint
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: seekingalpha
- Trial Results Disappointment: Elicio Therapeutics (ELTX) saw a ~72% drop in Monday trading after its Phase 2 trial for pancreatic ductal adenocarcinoma failed to meet the pre-specified primary endpoint of disease-free survival, indicating potential challenges in gaining market confidence moving forward.
- Safety and Tolerability Profile: Despite the disappointing results, the company highlighted the positive safety and tolerability profile of the asset, which supports the potential for longer-term administration and combination therapies, potentially attracting investor interest in its future developments.
- Strategic Development Adjustment: Elicio noted that the trial results will inform a refined Phase 3 development strategy focused on a defined R0 resected population and additional ELI-002 7P dosing, aiming to address significant unmet needs in the adjuvant setting and potentially opening new market opportunities.
- Financial Position and Financing Plans: The company stated that its current cash and cash equivalents will allow it to operate through Q4, while it is exploring multiple strategic financing and partnership opportunities to ensure future liquidity and business growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELTX
Wall Street analysts forecast ELTX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.710
Low
13.00
Averages
15.50
High
18.00
Current: 4.710
Low
13.00
Averages
15.50
High
18.00
About ELTX
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Elicio Therapeutics Reports Q1 2026 Losses Amid Failed Clinical Trial
- Clinical Trial Failure: Elicio Therapeutics' ELI-002 7P failed to meet the primary disease-free survival endpoint in the AMPLIFY-7P study, resulting in a staggering 72.53% drop in stock price in a single session, severely undermining investor confidence.
- Deteriorating Financials: The Q1 2026 earnings report revealed zero revenue and a widening net loss primarily driven by increased R&D expenses, indicating that the company's high-risk investments in clinical development have not yielded expected returns.
- Severe Market Reaction: Prior to the trial results announcement, B. Riley Securities issued a Buy rating with a $27 price target for ELTX, but following the trial failure, the stock closed at just $4.08, reflecting a pessimistic outlook from the market regarding the company's future prospects.
- Investor Rights Affected: With the significant stock decline, ELTX investors are encouraged to submit their information for legal support, highlighting potential misleading statements by the company that may have impacted investor decisions.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: Aditxt, Inc. (ADTX) surged 225% to $0.014 in pre-market trading, indicating strong market confidence in its growth potential, which may attract more investor interest.
- Other Gaining Stocks: Park Ha Biological Technology Co., Ltd. (BYAH) rose 40% to $1.68, while Spero Therapeutics, Inc. (SPRO) increased by 10% to $4.37, reflecting an overall positive sentiment in the biotech sector that could drive industry investment momentum.
- Pre-Market Losers: Elicio Therapeutics, Inc. (ELTX) fell 20% to $3.78, and Profusa, Inc. (PFSA) dropped 26% to $0.19, highlighting market concerns over certain companies, which may lead investors to reassess risks.
- Market Volatility Factors: The fluctuations in pre-market trading are primarily driven by U.S. patent protections, FDA approvals, manufacturing deals, and trial goal misses, showcasing the complexities and potential risks within the biotech industry.
See More
uniQure Shares Surge After FDA Softens Stance on Gene Therapy
- FDA Policy Shift: uniQure N.V. (QURE) shares surged 78.44% to $48.16 after the FDA accepted the 3-year analysis from its Phase I/II study as the primary basis for a Biologics License Application for AMT-130 in Huntington's disease, marking a significant regulatory milestone.
- Positive Cancer Vaccine Responses: Elicio Therapeutics Inc. (ELTX) reported that three patients in its Phase 2 AMPLIFY-7P study showed excellent responses to the experimental vaccine ELI-002 7P, leading to a 70.65% stock increase to $4.71, indicating potential for enhanced immunotherapy effectiveness.
- Key Company Developments: Lunai Bioworks (LNAI) saw its shares rise 40.06% to $4.00 as the CEO highlighted significant advancements, including a U.S. government defense contract and the development of an AI-driven precision neurology pipeline, positioning the company strategically in biotech and national security.
- Patent Application Boost: Polyrizon Ltd. (PLRZ) shares increased by 15.55% to $13.23 following the publication of a U.S. patent application for its nasal drug delivery technology, showcasing its innovative capabilities in the biotech sector and potential market impact.
See More
Elicio Therapeutics Reports Q1 2026 Loss Amid Failed Clinical Trial
- Clinical Trial Failure: Elicio Therapeutics' ELI-002 7P failed to meet the primary disease-free survival endpoint in the AMPLIFY-7P trial, resulting in a staggering 72.5% drop in stock price in a single day, causing significant losses for investors.
- Deteriorating Financials: The Q1 2026 earnings report revealed zero revenue and a widening net loss primarily driven by increased R&D expenses, indicating that the company's high-risk investments in clinical development have not yielded expected returns.
- Severe Market Reaction: Prior to the trial results announcement, B. Riley Securities had issued a Buy rating with a $27 price target, yet the stock plummeted to just $4.08 after the trial failure, reflecting a sharp decline in market confidence regarding the company's prospects.
- Investor Rights Affected: Following the stock crash, ELTX investors are encouraged to submit their information to participate in potential legal actions, suggesting that the company may have made misleading statements that impacted investor decisions.
See More
US Stocks Surge as Tech Leads Gains Amid Peace Deal
- Strong Market Performance: The S&P 500 rose by 1.65%, the Nasdaq 100 surged by 3.06%, and the Dow Jones Industrial Average hit a new record high, reflecting investor optimism about market prospects, particularly driven by gains in technology stocks.
- Crude Oil Price Plunge: WTI crude oil prices fell over 4% to a three-month low due to the US-Iran peace agreement and the reopening of the Strait of Hormuz, easing inflation expectations and boosting risk appetite in the equity markets.
- Weak Economic Data: The US June Empire Manufacturing Survey index dropped to 5.7, below the expected 13.7, indicating weakness in manufacturing that could pressure stocks, yet simultaneously supported gains in Treasury bonds.
- Tech Stocks Lead Gains: Chipmakers and AI infrastructure stocks performed strongly, with the iShares Semiconductor ETF rising over 5% and Western Digital up more than 15%, demonstrating strong market confidence in the technology sector.
See More
Elicio Therapeutics Faces Major Setback in Cancer Drug Trial
- Trial Results Disappoint: Elicio Therapeutics' ELI-002 7P failed to significantly delay cancer recurrence in surgically removed pancreatic cancer patients during its mid-stage study, leading to a more than 72% plunge in stock price on Monday, potentially marking the worst day in the company's history if losses persist.
- Patient Characteristic Imbalance: In the randomized trial involving 144 patients, a higher proportion of those with microscopic cancer remaining were in the treatment arm, which likely skewed overall results; however, in a significant subgroup where 84% had complete tumor removal, the median disease-free survival was 23.8 months compared to just 12.8 months for observation alone.
- Study Strategy Pivot: Elicio plans to refocus its late-stage study on lower-risk patients with clean surgical margins and extend treatment duration, while also exploring financing or partnership options, with cash expected to last into Q4 2026, as the CEO noted promising efficacy signals in patients with lower residual disease burden.
- Market Sentiment Shifts: Despite the stock's sharp decline, retail sentiment around ELTX surged from 'neutral' to 'extremely bullish' in the past 24 hours, with all three analysts covering the stock rating it a 'Buy' and a 12-month average price target of $20.67, indicating a potential upside of about 39% from the last closing price.
See More
Elicio Therapeutics Reports Q1 2026 Losses Amid Failed Clinical Trial
- Clinical Trial Failure: Elicio Therapeutics' ELI-002 7P failed to meet the primary disease-free survival endpoint in the AMPLIFY-7P study, resulting in a staggering 72.53% drop in stock price in a single session, severely undermining investor confidence.
- Deteriorating Financials: The Q1 2026 earnings report revealed zero revenue and a widening net loss primarily driven by increased R&D expenses, indicating that the company's high-risk investments in clinical development have not yielded expected returns.
- Severe Market Reaction: Prior to the trial results announcement, B. Riley Securities issued a Buy rating with a $27 price target for ELTX, but following the trial failure, the stock closed at just $4.08, reflecting a pessimistic outlook from the market regarding the company's future prospects.
- Investor Rights Affected: With the significant stock decline, ELTX investors are encouraged to submit their information for legal support, highlighting potential misleading statements by the company that may have impacted investor decisions.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: Aditxt, Inc. (ADTX) surged 225% to $0.014 in pre-market trading, indicating strong market confidence in its growth potential, which may attract more investor interest.
- Other Gaining Stocks: Park Ha Biological Technology Co., Ltd. (BYAH) rose 40% to $1.68, while Spero Therapeutics, Inc. (SPRO) increased by 10% to $4.37, reflecting an overall positive sentiment in the biotech sector that could drive industry investment momentum.
- Pre-Market Losers: Elicio Therapeutics, Inc. (ELTX) fell 20% to $3.78, and Profusa, Inc. (PFSA) dropped 26% to $0.19, highlighting market concerns over certain companies, which may lead investors to reassess risks.
- Market Volatility Factors: The fluctuations in pre-market trading are primarily driven by U.S. patent protections, FDA approvals, manufacturing deals, and trial goal misses, showcasing the complexities and potential risks within the biotech industry.
See More
uniQure Shares Surge After FDA Softens Stance on Gene Therapy
- FDA Policy Shift: uniQure N.V. (QURE) shares surged 78.44% to $48.16 after the FDA accepted the 3-year analysis from its Phase I/II study as the primary basis for a Biologics License Application for AMT-130 in Huntington's disease, marking a significant regulatory milestone.
- Positive Cancer Vaccine Responses: Elicio Therapeutics Inc. (ELTX) reported that three patients in its Phase 2 AMPLIFY-7P study showed excellent responses to the experimental vaccine ELI-002 7P, leading to a 70.65% stock increase to $4.71, indicating potential for enhanced immunotherapy effectiveness.
- Key Company Developments: Lunai Bioworks (LNAI) saw its shares rise 40.06% to $4.00 as the CEO highlighted significant advancements, including a U.S. government defense contract and the development of an AI-driven precision neurology pipeline, positioning the company strategically in biotech and national security.
- Patent Application Boost: Polyrizon Ltd. (PLRZ) shares increased by 15.55% to $13.23 following the publication of a U.S. patent application for its nasal drug delivery technology, showcasing its innovative capabilities in the biotech sector and potential market impact.
See More
Elicio Therapeutics Reports Q1 2026 Loss Amid Failed Clinical Trial
- Clinical Trial Failure: Elicio Therapeutics' ELI-002 7P failed to meet the primary disease-free survival endpoint in the AMPLIFY-7P trial, resulting in a staggering 72.5% drop in stock price in a single day, causing significant losses for investors.
- Deteriorating Financials: The Q1 2026 earnings report revealed zero revenue and a widening net loss primarily driven by increased R&D expenses, indicating that the company's high-risk investments in clinical development have not yielded expected returns.
- Severe Market Reaction: Prior to the trial results announcement, B. Riley Securities had issued a Buy rating with a $27 price target, yet the stock plummeted to just $4.08 after the trial failure, reflecting a sharp decline in market confidence regarding the company's prospects.
- Investor Rights Affected: Following the stock crash, ELTX investors are encouraged to submit their information to participate in potential legal actions, suggesting that the company may have made misleading statements that impacted investor decisions.
See More
US Stocks Surge as Tech Leads Gains Amid Peace Deal
- Strong Market Performance: The S&P 500 rose by 1.65%, the Nasdaq 100 surged by 3.06%, and the Dow Jones Industrial Average hit a new record high, reflecting investor optimism about market prospects, particularly driven by gains in technology stocks.
- Crude Oil Price Plunge: WTI crude oil prices fell over 4% to a three-month low due to the US-Iran peace agreement and the reopening of the Strait of Hormuz, easing inflation expectations and boosting risk appetite in the equity markets.
- Weak Economic Data: The US June Empire Manufacturing Survey index dropped to 5.7, below the expected 13.7, indicating weakness in manufacturing that could pressure stocks, yet simultaneously supported gains in Treasury bonds.
- Tech Stocks Lead Gains: Chipmakers and AI infrastructure stocks performed strongly, with the iShares Semiconductor ETF rising over 5% and Western Digital up more than 15%, demonstrating strong market confidence in the technology sector.
See More
Elicio Therapeutics Faces Major Setback in Cancer Drug Trial
- Trial Results Disappoint: Elicio Therapeutics' ELI-002 7P failed to significantly delay cancer recurrence in surgically removed pancreatic cancer patients during its mid-stage study, leading to a more than 72% plunge in stock price on Monday, potentially marking the worst day in the company's history if losses persist.
- Patient Characteristic Imbalance: In the randomized trial involving 144 patients, a higher proportion of those with microscopic cancer remaining were in the treatment arm, which likely skewed overall results; however, in a significant subgroup where 84% had complete tumor removal, the median disease-free survival was 23.8 months compared to just 12.8 months for observation alone.
- Study Strategy Pivot: Elicio plans to refocus its late-stage study on lower-risk patients with clean surgical margins and extend treatment duration, while also exploring financing or partnership options, with cash expected to last into Q4 2026, as the CEO noted promising efficacy signals in patients with lower residual disease burden.
- Market Sentiment Shifts: Despite the stock's sharp decline, retail sentiment around ELTX surged from 'neutral' to 'extremely bullish' in the past 24 hours, with all three analysts covering the stock rating it a 'Buy' and a 12-month average price target of $20.67, indicating a potential upside of about 39% from the last closing price.
See More
